Veracyte

Veracyte EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Veracyte (VCYT) as of Oct 10, 2026 is 82.06 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 24.81 M USD — a change of 230.79% (higher).

EBITDA

82.06 MUSD

YoY

230.79%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Veracyte is 2025 82.06 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Veracyte was 2024 24.81 M USD. It decreases by 230.79% higher compared to the previous year.

The Veracyte EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-17.94 M USD
Jan 1, 2019
-12.03 M USD
Jan 1, 2020
-28.49 M USD
Jan 1, 2021
-63.80 M USD
Jan 1, 2022
-16.98 M USD
Jan 1, 2023
-60.80 M USD
Jan 1, 2024
24.81 M USD
Jan 1, 2025
82.06 M USD
The Veracyte EBITDA history
YEAREBITDAYoY
82.06 MUSD+230.79%
24.81 MUSD-140.80%
-60.80 MUSD+258.04%
-16.98 MUSD-73.39%
-63.80 MUSD+123.96%
-28.49 MUSD+136.88%
-12.03 MUSD-32.94%
-17.94 MUSD-32.33%
-26.51 MUSD-3.62%
-27.50 MUSD-15.81%
-32.67 MUSD+14.59%
-28.51 MUSD—
Access this data via the Eulerpool API

Veracyte Stock analysis

What does Veracyte do? Veracyte Inc is a company that specializes in the development and marketing of diagnostic tests for a wide range of diseases and disorders. The company was founded in 2008 and is headquartered in South San Francisco, California. The history of Veracyte Inc begins with the vision to help patients with better diagnostic options. The company has used its expertise in gene expression technology to develop tests that facilitate the diagnosis of diseases and disorders in various areas, such as cancer, thyroid diseases, and lung diseases. Veracyte Inc's business model is based on selling diagnostic tests to healthcare facilities, hospitals, doctors, and other medical institutions. The tests are performed by specially trained professionals and can provide a precise diagnosis that helps doctors plan individualized treatment. Veracyte Inc is divided into different divisions to offer the best and most precise test for each area. The divisions include cancer diagnosis, thyroid diagnostics, lung diagnostics, and other areas of gene expression technology. In cancer diagnosis, Veracyte Inc offers tests for various types of cancer, such as breast cancer, thyroid cancer, and lung cancer. The tests use RNA sequencing to analyze the patient's genetic information and provide a more precise diagnosis. In thyroid diagnostics, Veracyte Inc offers tests for various thyroid diseases that are often difficult to diagnose. The tests help avoid unnecessary surgeries or medical interventions and enable patients to receive a more accurate diagnosis and treatment. In lung diagnostics, Veracyte Inc offers tests for pneumonia, lung cancer, and other lung diseases. The tests use RNA sequencing and imaging to provide accurate diagnoses that help doctors recommend tailored treatment. In addition to these divisions, Veracyte Inc also offers other products and services, such as information campaigns and training for healthcare professionals, as well as support and counseling for patients and their families. Overall, Veracyte Inc aims to revolutionize the medical field and provide patients with better diagnosis and treatment options. The company's tests offer doctors and patients a more precise and personalized diagnosis, allowing for individualized treatment and achieving the best results. Veracyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Veracyte stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Veracyte is 82.06 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Veracyte changed from 24.81 M USD to 82.06 M USD, representing a 230.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Veracyte since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Veracyte historically and in real time.

Access this data via the Eulerpool API

Income Statement — Veracyte

All Key Metrics — Veracyte